Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23598171 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions: Brain and Central Nervous System Tumors;   Lymphoma;   Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib;   Other: pharmacogenomic studies;   Other: pharmacological study

Indicates status has not been verified in more than two years